Navigation Links
Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer

FOLFOX4 Chemotherapy Results in Improved Long-term [Five-years] Overall Survival for these Seriously Ill Patients

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- FOLFOX4, an Eloxatin(R)-based chemotherapy regimen, provided significant improvements in long-term [five- years] overall survival (OS) and time to disease progression (TTP) - a longer period of stable disease - in patients with metastatic (advanced) colorectal cancer. Importantly, the FOLFOX4 results were significantly better than those achieved with irinotecan-based chemotherapy, known as IFL, and IROX, a combination of irinotecan and Eloxatin(R). These data were presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago in an updated analysis of the N9741 study.

FOLFOX4 (Eloxatin(R) combined with infusional 5-FU/LV) was established in the United States as first line treatment for advanced colorectal cancer after the initial presentation of the N9741 study results in 2003 and subsequent Food and Drug Administration (FDA) approval in January 2004. The updated analysis confirms the earlier results and identifies FOLFOX4 chemotherapy as the strongest predictor of improvement in both overall survival and time to disease progression.

N9741 Five-Year Analysis

This study evaluated several chemotherapy regimens using various combinations of Eloxatin(R), 5-FU/LV and irinotecan in 1,691 previously untreated patients with metastatic colorectal cancer who were randomized to seven arms.

Metastatic colorectal cancer patients given the Eloxatin(R)-based regimen FOLFOX4 were almost twice as likely to survive at least five years as those on irinotecan-based therapy (IFL). Five-year survival and time-to-progression rates were calculated using Kaplan-Meier methods for each treatment arm. Patients treated with FOLFOX4 had a 9.2% overall chance of surviving for five years after treatment, the best
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
2. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
3. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
4. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
5. Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
8. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
Post Your Comments:
(Date:12/19/2014)... YORK , Dec. 18, 2014 Somewhere ... addressing hearing health was forgotten. But Audicus , ... to hear better this new year. Hearing ... facing the aging population, though it is often unaddressed. ... in four has a hearing aid, mainly due to ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... , INDIANAPOLIS, Aug. 10 Acquire ... fabrication and integration and automation services, has recently expanded ... in its focus on a long-term goal of becoming ... North America. , , Acquire Automation ...
... SEATTLE, Aug. 7 Regular yoga practice is associated ... to be obese, according to a study led by researchers at ... study was prompted by initial findings reported four years ago by ... may help prevent middle-age spread in normal-weight people and may promote ...
Cached Medicine Technology:Vision Inspection Systems Specialist Acquire Automation Expands Employee Base, Launches New Web Site 2Regular Yoga Practice Is Associated With Mindful Eating 2Regular Yoga Practice Is Associated With Mindful Eating 3Regular Yoga Practice Is Associated With Mindful Eating 4
(Date:12/19/2014)... Rosa, CA (PRWEB) December 19, 2014 ... and 5x5 SuperClone Rooms. SuperCloset continues to offer indoor ... solutions. Pair one of the new SuperClone Rooms with ... professional, perpetual, and turnkey indoor hydroponic grow room setup. ... in the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... These vanadium reserves are mostly found in ... tons of vanadium were produced globally in 2013, up ... at 6.7% AAGR during the period from 2001 to ... the largest consumer, accounted for more than 90% of ... and the chemical industry. , View Full Report at ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 The Medspa ... new injectable filler from respected cosmetic brand Juvéderm. Voluma ... naturally with age. The Medspa at Hendrick is pleased ... in skin care technology to its clients. , Voluma ... to be FDA-approved to treat the mid-face and cheek ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- New research warns parents that buying ... at risk. Nearly half of teen drivers killed in the ... at least 11 years old and often lacked important safety features ... percent of teen drivers killed in crashes were in cars at ... 10 years old, 31 percent were in cars 11 to 15 ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- All children should have ... 6, preferably every year, eye experts say. The ... expert panel of the U.S. National Center for Children,s ... this age group require screening for eye problems, particularly ... as amblyopia ("lazy eye") and strabismus (a disorder of ...
Breaking Medicine News(10 mins):Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Preschoolers Need Eye Screening, Experts Say 2
... ... year old Mitchell Brown ( www.helpmitchell.com ), an athlete, loving young father, and lifetime resident of ... months before the birth of his second child. , ... East Brunswick, NJ (Vocus) September 3, 2009 -- The race is on to find ...
... goal, researchers say , THURSDAY, Sept. 3 (HealthDay News) -- ... to cooperate, researchers at Harvard University and the Stockholm School ... a stick. , In certain situations "where people interact ... our work suggests that rewards result in better outcomes than ...
... , BROOMFIELD, Colo., Sept. 3 Embla(R) and ... acquire Covidien,s Sleep Diagnostic business. This includes the sleep diagnostic products ... transaction were not disclosed. Completion of the sale is subject to ... will form the world,s largest company to focus entirely on sleep ...
... Unanimous Decision on Med Mal, Negligence, and TAPA Claims , ... favor of the estate of Mrs. Voncil Sherrod, who died on 3/24/05 ... Rehabilitation, a Mariner Health Care nursing home in Tennessee. Counsel for ... of the firm Marks, Balette & Giessel, P.C. and Matthew Mussalli. , ...
... China, Sept. 3 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the ... D, Rule 504 offering and is no longer selling shares ... will be filed with the Securities and Exchange Commission shortly, ... over the past twelve months. The limit to any such ...
... Ga., Sept. 3 Aflac Incorporated (NYSE: AFL ) ... Bruyette, & Woods 2009 Insurance Conference. Chairman and Chief Executive ... scheduled to make a presentation on September 10, 2009, at 2:05 ... discuss the company,s outlook for 2009 and its strategy for growth ...
Cached Medicine News:Health News:Jewish Stem Cell Donor Urgently Sought for Young NJ Man Battling Aggressive Non-Hodgkin Lymphoma 2Health News:Jewish Stem Cell Donor Urgently Sought for Young NJ Man Battling Aggressive Non-Hodgkin Lymphoma 3Health News:Rewards Are Key to Cooperation 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2Health News:Arbitration Panel Finds in Favor of Tennessee Victim of Mariner Nursing Home Negligence 2Health News:Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering 2Health News:Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering 3Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2009 Insurance Conference 2
... Used for stone manipulation and removal in ... the basket to retain its shape following extreme ... stone capture by allowing the basket to open ... the stone. The tipless design reduces the likelihood ...
... Perc NCircle® is designed to provide rapid ... The Perc NCircle combines traditional surgical instrument ... tipless basket technology. The small, flexible ... allows the surgeon to remove larger stones ...
... Used for temporary internal drainage ... bladder. Supplied sterile in peel-open packages. ... evaluation is advised; C-Flex® and Sof-Flex® ... than six (6) months; silicone stents ...
... ACMI Classic Double Pigtail Ureteral ... pigtail design that maximizes migration. They ... added versatility and cost savings. ... Kit contains one Classic Double PigTail ...
Medicine Products: